JP7684971B2 - 新規の細胞内送達方法 - Google Patents

新規の細胞内送達方法 Download PDF

Info

Publication number
JP7684971B2
JP7684971B2 JP2022538169A JP2022538169A JP7684971B2 JP 7684971 B2 JP7684971 B2 JP 7684971B2 JP 2022538169 A JP2022538169 A JP 2022538169A JP 2022538169 A JP2022538169 A JP 2022538169A JP 7684971 B2 JP7684971 B2 JP 7684971B2
Authority
JP
Japan
Prior art keywords
cpp
amino acid
seq
peptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511501A5 (OSRAM
JP2023511501A (ja
Inventor
ストーン，シェイン
ホール，クリントン
スターンワイス，アニャ
カニンガム，ポーラ
Original Assignee
ピーワイシー セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904882A external-priority patent/AU2019904882A0/en
Application filed by ピーワイシー セラピューティクス リミテッド filed Critical ピーワイシー セラピューティクス リミテッド
Publication of JP2023511501A publication Critical patent/JP2023511501A/ja
Publication of JP2023511501A5 publication Critical patent/JP2023511501A5/ja
Application granted granted Critical
Publication of JP7684971B2 publication Critical patent/JP7684971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
JP2022538169A 2019-12-20 2020-12-18 新規の細胞内送達方法 Active JP7684971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904882 2019-12-20
AU2019904882A AU2019904882A0 (en) 2019-12-20 Novel Cellular Delivery Methods
PCT/AU2020/051397 WO2021119756A1 (en) 2019-12-20 2020-12-18 Novel cellular delivery methods

Publications (3)

Publication Number Publication Date
JP2023511501A JP2023511501A (ja) 2023-03-20
JP2023511501A5 JP2023511501A5 (OSRAM) 2023-12-21
JP7684971B2 true JP7684971B2 (ja) 2025-05-28

Family

ID=76476454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538169A Active JP7684971B2 (ja) 2019-12-20 2020-12-18 新規の細胞内送達方法

Country Status (10)

Country Link
US (1) US20230048338A1 (OSRAM)
EP (1) EP4077354A4 (OSRAM)
JP (1) JP7684971B2 (OSRAM)
KR (1) KR20220117914A (OSRAM)
CN (1) CN115190884B (OSRAM)
AU (1) AU2020406670B2 (OSRAM)
BR (1) BR112022012057A2 (OSRAM)
CA (1) CA3161901A1 (OSRAM)
IL (1) IL294050A (OSRAM)
WO (1) WO2021119756A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
US20250114464A1 (en) * 2022-01-27 2025-04-10 The Governors Of The University Of Alberta Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases
WO2024073042A1 (en) * 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
WO2025238644A1 (en) * 2024-05-16 2025-11-20 Skip Therapeutics Ltd. Compositions and methods for treating retinal diseases
WO2025240993A1 (en) * 2024-05-24 2025-11-27 PYC Therapeutics Limited Improved cell penetrating peptides and related compositions and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081581A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US20070044171A1 (en) 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
JP2014514365A (ja) 2011-05-13 2014-06-19 ケベンハウンス ウニヴェルジテート（ユニバーシティ オブ コペンハーゲン） 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤
US20170349628A1 (en) 2014-10-02 2017-12-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019018898A1 (en) 2017-07-28 2019-01-31 Phylogica Limited CELL PENETRATING PEPTIDES AND RELATED COMPOSITIONS AND METHODS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186347A1 (en) * 2010-06-14 2013-01-30 Hoffmann La Roche Cell-penetrating peptides and uses therof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081581A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20070044171A1 (en) 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
JP2014514365A (ja) 2011-05-13 2014-06-19 ケベンハウンス ウニヴェルジテート（ユニバーシティ オブ コペンハーゲン） 虚血性脳損傷及び疼痛治療用の効率的な神経保護剤としてのｐｓｄ−９５の高親和性二量体阻害剤
US20170349628A1 (en) 2014-10-02 2017-12-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019018898A1 (en) 2017-07-28 2019-01-31 Phylogica Limited CELL PENETRATING PEPTIDES AND RELATED COMPOSITIONS AND METHODS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta，2013年，Vol.1828，pp.1484-1493
J. Nanobiotechnol.，2017年，Vol.15, No.34，pp.1-18
SCIENTIFIC REPORTS，2018年，Vol.8, No.11256，pp.1-10

Also Published As

Publication number Publication date
CN115190884B (zh) 2026-01-13
IL294050A (en) 2022-08-01
BR112022012057A2 (pt) 2022-08-30
AU2020406670B2 (en) 2026-03-05
JP2023511501A (ja) 2023-03-20
EP4077354A1 (en) 2022-10-26
CA3161901A1 (en) 2021-06-24
EP4077354A4 (en) 2024-01-24
AU2020406670A1 (en) 2022-07-14
WO2021119756A1 (en) 2021-06-24
CN115190884A (zh) 2022-10-14
KR20220117914A (ko) 2022-08-24
US20230048338A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
AU2020406670B2 (en) Novel cellular delivery methods
CN110291100B (zh) 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
Ramsey et al. Cell-penetrating peptides transport therapeutics into cells
US9303076B2 (en) Cell-penetrating peptides and uses thereof
US20210087238A1 (en) Cell penetrating peptides and related compositions and methods
Jha et al. CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes
JP2009527251A (ja) 細胞膜透過性ペプチド
Kato et al. Cell-penetrating helical peptides having L-arginines and five-membered ring α, α-disubstituted α-amino acids
Buyanova et al. Discovery of a cyclic cell-penetrating peptide with improved endosomal escape and cytosolic delivery efficiency
Wu et al. Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis
JPWO2008123180A1 (ja) 標的物質の検出方法、並びに、これに用いるタグ、ｄｎａ、ベクター、プローブ及び検出キット
US20200360529A1 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
Schissel et al. In-cell penetration selection–mass spectrometry produces noncanonical peptides for antisense delivery
Nanda et al. 4 (R/S)-Guanidinylprolyl collagen peptides: on-resin synthesis, complexation with plasmid DNA, and the role of peptides in enhancement of transfection
RU2842811C1 (ru) Новые способы доставки в клетку
KR20090122769A (ko) 세포내로 단백질을 전달하는 방법 및 이를 위한 펩타이드
Horikoshi et al. Dual-modified penetratin peptides: Enhancing nucleic acid delivery through stapling and endosomal escape domain
Wen Development and Application of Cell Penetrating Beta-Hairpin and Alpha-Helical Peptides
Nore A synthetic cell-penetrating peptide (CPP) with protamine conjugate utilized for gene delivery
HK1180232B (en) Cell-penetrating peptides and uses thereof
SAXENA In-Silico Designing, Synthesis and Modification of Papilloma based CPPs in Drug Delivery Thesis
HK1180232A (en) Cell-penetrating peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220809

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220713

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250516

R150 Certificate of patent or registration of utility model

Ref document number: 7684971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150